INKT

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Mink Therapeutics Inc

NASDAQ | INKT

10.51

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$52.39M

Market Cap

-

P/E Ratio

-2.93

EPS

$76.00

52 Week High

$4.56

52 Week Low

HEALTHCARE

Sector

INKT Chart

Recent Chart
Price Action

INKT Technicals

Tags:

INKT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$215K
Total Revenue $0
Cost Of Revenue $215K
Costof Goods And Services Sold $215K
Operating Income -$11M
Selling General And Administrative $4.3B
Research And Development $6.3M
Operating Expenses $10M
Investment Income Net -
Net Interest Income $173K
Interest Income $173K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $215K
Income Before Tax -$11M
Income Tax Expense -$11B
Interest And Debt Expense -
Net Income From Continuing Operations -$11M
Comprehensive Income Net Of Tax -
Ebit -$11M
Ebitda -$11M
Net Income -$11M

Revenue & Profitability

Earnings Performance

INKT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $5.7M
Total Current Assets $5M
Cash And Cash Equivalents At Carrying Value $4.6M
Cash And Short Term Investments $4.6M
Inventory -
Current Net Receivables -
Total Non Current Assets $733K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $4.6B
Other Current Assets $411K
Other Non Current Assets -
Total Liabilities $25M
Total Current Liabilities $7M
Current Accounts Payable $2.7M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $18M
Capital Lease Obligations -
Long Term Debt $4.9M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $4.9M
Other Current Liabilities $4.2M
Other Non Current Liabilities -
Total Shareholder Equity -$20M
Treasury Stock -
Retained Earnings -$144M
Common Stock $40
Common Stock Shares Outstanding $3.9M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$9.6M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $215K
Capital Expenditures $4
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$11M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$215K
Total Revenue $0
Cost Of Revenue $215K
Costof Goods And Services Sold $215K
Operating Income -$11M
Selling General And Administrative $4.3B
Research And Development $6.3M
Operating Expenses $10M
Investment Income Net -
Net Interest Income $173K
Interest Income $173K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $215K
Income Before Tax -$11M
Income Tax Expense -$11B
Interest And Debt Expense -
Net Income From Continuing Operations -$11M
Comprehensive Income Net Of Tax -
Ebit -$11M
Ebitda -$11M
Net Income -$11M

INKT News

INKT Profile

Mink Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, dedicated to developing innovative allogeneic invariant natural killer T-cell therapies aimed at addressing cancer and immune-mediated diseases. With a focus on harnessing the unique properties of these immune cells, MiNK is positioning itself at the forefront of next-generation cell-based immunotherapies. The company is committed to pioneering novel treatment options that have the potential to significantly enhance patient outcomes and transform therapeutic strategies in the oncology and immunology landscapes.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
INHD
-0.99%
$0.22
TSLA
+0.84%
$430.17
CHR
-3.48%
$0.04
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
BMNU
+8.77%
$8.18
ONMD
+30.28%
$1.85
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
WLGS
-5.57%
$0.04
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
MTSR
-0.35%
$70.50
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
ACHR
+4.00%
$7.79
GRAB
+2.44%
$5.45
AFMD
-34.94%
$0.18
DVLT
-4.69%
$2.03
PFE
+0.11%
$25.74
CAN
+0.75%
$0.92
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
WBD
+0.50%
$24.00
VEEE
+45.50%
$2.59
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
NGD
+6.76%
$8.37
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.76%
$17.28
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.30%
$2.44
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
META
-0.41%
$633.61
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+1.89%
$3.22
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
INHD
-0.99%
$0.22
TSLA
+0.84%
$430.17
CHR
-3.48%
$0.04
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
BMNU
+8.77%
$8.18
ONMD
+30.28%
$1.85
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
WLGS
-5.57%
$0.04
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
MTSR
-0.35%
$70.50
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
ACHR
+4.00%
$7.79
GRAB
+2.44%
$5.45
AFMD
-34.94%
$0.18
DVLT
-4.69%
$2.03
PFE
+0.11%
$25.74
CAN
+0.75%
$0.92
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
WBD
+0.50%
$24.00
VEEE
+45.50%
$2.59
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
NGD
+6.76%
$8.37
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
CDE
+6.76%
$17.28
PLTR
+1.61%
$168.45
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.30%
$2.44
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
META
-0.41%
$633.61
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+1.89%
$3.22
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.